Lundbeck pivot emphasizes first in class in revamped pipeline

Decades into its story, Lundbeck is breaking from its classical psychiatry small molecule core to take on a more innovation-focused R&D strategy, adding the company to the pool of potential partners for biotechs translating new neuroscience into therapies. 

The shift, kicked off with the appointment of Deborah Dunsire as president and CEO in 2018, brings H. Lundbeck A/S (CSE:LUN) into closer alignment with the latest class of biotechs that is looking beyond well-established mechanisms in neuroscience and finding new ways to intervene in the pathways...